louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06072651: Mother-Baby Study - Relative Reinforcing Value (RRV)
Official title: Fundamental Biobehavioral Mechanisms Underlying the Integrated Development of Emotion, Attachment, and Nutritive Intake in the Mother-Infant Dyad
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Eating Behavior
Keywords: eating behavior
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2023-10-10
Enrollment: 120
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The study will test a model of biobehavioral mechanisms involved in the development of a system of emotion, attachment, and nutritive intake in the mother-infant dyad and the association of this system with maternal feeding behavior, child eating behavior, dietary intake, and adiposity.

To participate in this study the infant must also be enrolled in long-term observational study, NCT06039878.

Detailed description: This interventional task is done with children while they are in the long-term observational study, NCT06039878, at approximately ages 18 and 36 months. In the observational study there are 240 participants (120 mothers and 120 children). In this trial only data from the children is collected and therefore only 120 participants are listed.

Eligibility criteria: The child is a participant in the observational study (NCT06039878).

Primary outcomes:
measure: Relative Reinforcing Value (RRV) of food
timeFrame: Up to approximately 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Julie Lumeng, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06969651: Effects of Racial Congruence, "Likes", and Food Images in Social Media Ads on Adolescents' Caloric Intake - Study 3
Official title: Comparing the Effects of Racial Congruence, "Likes," and Food Images in Social Media Ads on Adolescents' Caloric Intake - Study 3
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Calorie Consumption
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Cancer Institute (NCI)
name: New York University
First posted: 2025-05-14
Enrollment: 480
Sex: ALL
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Within-Subjects Block Design
Primary purpose: PREVENTION

Brief summary: This is a randomized trial to to test the degree to which visual attention to unhealthy foods, racially congruent people, and/or "likes" in social media ads explains the relationship between ad exposure and calorie intake.

Detailed description: This is a randomized trial to to test the degree to which visual attention to unhealthy foods, racially congruent people, and/or "likes" in social media ads explains the relationship between ad exposure and calorie intake.

Eligibility criteria: Inclusion Criteria:

* adolescent (13-17 years of age) who identifies as only non-Latino White or only Black/African American; who logs into Instagram once daily; who can read and speak English

Exclusion Criteria:

* - participants who do not meet all criteria described above

Primary outcomes:
measure: Caloric Intake
timeFrame: Day 0 (Approximately 60 minutes)
measure: Visual Attention to Ad Features - First Fixation
timeFrame: Day 0 (Approximately 60 minutes)
measure: Visual Attention to Ad Features - Gaze Duration
timeFrame: Day 0 (Approximately 60 minutes)
measure: Visual Attention to Ad Features - Number of Fixations
timeFrame: Day 0 (Approximately 60 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Health
state: New York
Study officials:
affiliation: NYU Langone Health
name: Marie A. Bragg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00922051: Acute Effects of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Forced Expiratory Flow Volume in One Second (FEV1) and Blood β-Endorphin Level in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Official title: Acute Effects of Acu-TENS on FEV1 and Blood β-Endorphin Level in Subjects With COPD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: COPD
FEV1
beta endorphin
TENS
acupuncture
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2009-06-17
Enrollment: 44
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The objective of this study is to investigate the effectiveness of Acu-TENS (transcutaneous electrical nerve stimulation applied on acupoints) on lung functions, dyspnoeic symptoms and its association with beta endorphin level in subjects with COPD.


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis with COPD

Exclusion Criteria:

* allergic to gel
* unable to perform spirometry
* unable to communicate

Primary outcomes:
measure: Forced expiratory flow volume in one second (FEV1), forced vital capacity (FVC)
timeFrame: measured before and after intervention
Secondary outcomes:
measure: Beta endorphin
timeFrame: before and after intervention
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Hospital
state: Sichuan
Study officials:
affiliation: The Hong Kong Polytechnic University
name: Alice Jones, PhD, FACP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002451: Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
Official title: A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Activity of Indinavir Sulfate 1200 Mg q.d. and Ritonavir 200 Mg q.d. in Combination With Stavudine and Lamivudine in Treatment Naive HIV-1 Infected Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: HIV Infections
Keywords: Drug Therapy, Combination
Stavudine
HIV Protease Inhibitors
CD4 Lymphocyte Count
Ritonavir
Lamivudine
Indinavir
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy. This study will look at the effectiveness of this drug combination and side effects.

Detailed description: Patients entering this study initiate antiretroviral therapy. For 24 weeks patients receive daily dosages of IDV, RTV, 3TC, and d4T. Patients are seen at Day 1 and at Weeks 2, 4, 8, 12, 16, 20, and 24 for physical examinations, pregnancy testing, and blood sampling to monitor CD4 count and viral load. On Day 14, blood is drawn frequently for 24 hours for IDV and RTV pharmacokinetic sampling. The incidence of serious and drug-related adverse events and of adverse events leading to study discontinuation is tabulated.

Eligibility criteria: Inclusion Criteria

Patients may be eligible for this study if they:

* Are HIV-positive.
* Are at least 18 years old.
* Have a viral load of 5,000 copies/ml or greater.
* Have a CD4 count of at least 50 cells/mm3.

Exclusion Criteria

Patients will not be eligible for this study if they:

* Have taken any antiretroviral (anti-HIV) agent.
* Are pregnant.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: Univ of Miami School of Medicine
state: Florida
city: Albany
country: United States
facility: Albany Med College
state: New York
city: Stony Brook
country: United States
facility: SUNY at Stony Brook / Division of Infectious Diseases
state: New York
Study officials:
References:
Clinical trial NCT02993354: Noninvasive Monitoring of Uterine Electrical Activity and Fetal Heart Rate: A New External Monitoring Device
Official title: Noninvasive Monitoring of Uterine Electrical Activity and Fetal Heart Rate: A New External Monitoring Device
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Contraction
Lead sponsor: Montefiore Medical Center
Sponsor class: OTHER
First posted: 2016-12-15
Enrollment: 48
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women

Brief summary: The EUM (electrical uterine myography) (OB Tools, Israel) was tested and found to be reliable as a non-invasive method for evaluating uterine contractions and the fetal heart rate. It is safe and effective in monitoring uterine contractions. The investigators propose to perform a study to validate the accuracy and clinical usefulness of the EUM device by simultaneously monitoring obese patients with current method of external tocodynamometry with the EUM device. Providers will be blinded to the results of the EUM device. Caregivers will continue care as per current guidelines using the information obtained from the current monitoring methods. Information obtained from the EUM devices will not be used to determine the clinical course of action.

Detailed description: Purpose:

The investigators propose to perform a study to validate the accuracy and clinical usefulness of the EUM device by comparing it with simultaneous use of current methods (external tocodynamometry) among obese patients.

Objective:

Compare the interpretability of the contractions recorded using the EUM device vs. those obtained from external tocodynamometer among obese pregnant women.

Eligibility criteria: Inclusion Criteria:

1. Maternal age \>18 years old
2. Singleton pregnancy
3. Gestational age of 24 completed weeks or greater based on the estimated due date as calculated from last menstrual period or early ultrasound
4. Category I (reassuring) fetal heart rate tracing at time of enrollment

Exclusion Criteria:

1. Fetal anomaly or chromosome defect
2. Allergy to silver
3. Woman with implanted electronic device of any kind
4. Irritated skin or open wound on the abdominal wall

Primary outcomes:
measure: Continuity in Readings of Contractions
timeFrame: within 4 hours of device application
measure: Continuity in Readings of Fetal Heart Rate
timeFrame: within 4 hours of device application
Secondary outcomes:
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Jack D. Weiler Hospital of Montefiore Medical Center
state: New York
Study officials:
affiliation: Montefiore Medical Center
name: Peter Bernstein, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Moni SS, Kirshenbaum R, Comfort L, Kuba K, Wolfe D, Xie X, Negassa A, Bernstein PS. Noninvasive monitoring of uterine electrical activity among patients with obesity: a new external monitoring device. Am J Obstet Gynecol MFM. 2021 Jul;3(4):100375. doi: 10.1016/j.ajogmf.2021.100375. Epub 2021 Apr 20.
Clinical trial NCT05078554: HPV and Male Homosexuality in General Practice?
Official title: HPV Vaccination (Human Papilloma Virus), or How to Address Male Homosexuality in General Practice in Alsace?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Papilloma Viral Infection
Keywords: Papilloma Viral Infection
HPV
HPV vaccine
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-10-14
Enrollment: 15
Sex: MALE
Minimum age (years): 18
Maximum age (years): 26
Standard ages: ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjetc aged between 18-26 years consulting at the HUS Cegidd as part of an STI screening

Brief summary: The main objective of this study is to find out whether young MSM (men who have sex with men) believe it is important for their GP to be informed of their sexual orientation, in order to improve their clinical, especially with HPV vaccination.

The secondary objective is to analyze the state of knowledge about the HPV vaccine and the value of HPV vaccine in this target population.


Eligibility criteria: Inclusion criteria:

* Age: 18-26 years
* Consultation at the HUS Cegidd as part of an STI screening
* Subject who expressed no opposition to participating in the study

Exclusion criteria:

* Refusal of the patient to participate in the study
* Subject who had already benefited from HPV vaccination (at least one dose)
* Inability to give informed consent
* Subject under safeguarde of justice
* Subject under guardianship or under curatorship

Primary outcomes:
measure: Retrospective descriptive study of vaccination against HPV (Human Papilloma Virus) in Alsace?
timeFrame: Files analysed retrospectively from April 27, 2021 to January 27, 2020 will be examined]
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service du Trait d'Union - Hôpitaux Universitaires de Strasbourg
Study officials:
References:
Clinical trial NCT03115554: Comparison of PVI Plus Catheter Ablation or PVI Alone for the Treatment of AFib for Patients With Paroxysmal Atrial Fibrillation
Official title: Comparison of Pulmonary Vein Isolation Plus Additional Catheter Ablation or Pulmonary Vein Isolation Alone for the Treatment of Atrial Fibrillation for Patients With Paroxysmal Atrial Fibrillation: A Prospective, Randomized Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Atrial Fibrillation
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2017-04-14
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There is a need to compare the efficacy of PVI versus PVI plus catheter ablation, which includes ablation of complex fractionated atrial electrograms (CFAE) and linear lesions in the same procedure. If it is found that the PVI alone is as effective as PVI plus catheter ablation of CFAE and linear lesions, it may reduce the need for catheter ablation.


Eligibility criteria: Inclusion Criteria:

(Step 1 - Registration)

* The subject is 18 years of age or older
* Left atrium \< 6.0 cm (Trans Thoracic Echo - TTE - parasternal 4 chamber view
* performed within 6 months)
* Documentation of AF that terminates spontaneously or with intervention within 7 days of onset (PAF) Failed or refractory to one AAD (class I and/or III)
* Provided written informed consent
* Be eligible for an AF ablation procedure for Paroxysmal AF

(Step 2 - Randomization)

* Sustained AF following PVI with ability to receive additional linear or focal intracardiac catheter ablation

Exclusion Criteria:

(Step 1 - Registration)

* Pregnant or planning to become pregnant during study
* Co-morbid medical conditions that limit one-year life expectancy
* Previous cardiac surgery
* Patients who have active infection or sepsis
* Patients with esophageal ulcers strictures and varices
* Patients who are contraindicated for anticoagulants such as heparin and warfarin
* Patients who are being treated for ventricular arrhythmias
* Patients who have had a previous left atrial catheter ablation for AF (does not
* include ablation for AFL or other supraventricular arrhythmias)
* Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment
* Not competent to legally represent him or herself (e.g., requires a guardian or
* caretaker as a legal representative)

(Step 2 Randomization)

* Not able to receive additional linear or focal intracardiac catheter ablation

Primary outcomes:
measure: Time to recurrence
timeFrame: 12 months
Secondary outcomes:
measure: Time to recurrence following intervention
timeFrame: 12 months post intervention
Other outcomes:
Locations:
city: Milwaukee
country: United States
facility: Aurora Health Care
state: Wisconsin
Study officials:
affiliation: Wake Forest University Health Sciences
name: Jasbir Sra, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04515654: Supporting Trans Identities and Occupational Justice Through Narrative Informed Theatre: Supporting Trans Identities and Occupational Justice Through Narrative Informed Theatre
Official title: Supporting Trans Identities and Occupational Justice Through Narrative Informed Theatre: A Mixed-methods Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Transgenderism
Stigma, Social
Keywords: gender
drama
disability studies
qualitative
stigma
affirmative care
minority health
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2020-08-17
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Importance: Societal stigma gravely impedes occupational justice for trans individuals, producing vast health disparities for this population.

Objective: Test feasibility and impact of an intervention to reduce stigma and improve trans wellbeing Design: Convergent parallel mixed methods Setting: Community/Webinar Participants: 42 audience members and 6 trans interviewees Intervention: Virtual, narrative-informed play reading and moderated discussion about gender diversity and affirmative care Outcomes and Measures: The valid and reliable Acceptance and Action Questionnaire - Stigma (AAQ-S) assesses stigma beliefs; An open-ended qualitative question assesses trans interviewees' experiences


Eligibility criteria: Inclusion Criteria:

* age 18 or older

Exclusion Criteria:

* none

Primary outcomes:
measure: Acceptance and Action Questionnaire-stigma
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Indiana University Purdue University Indianapolis
state: Indiana
Study officials:
References:
Clinical trial NCT01469754: Longitudinal Survey Analysis in Lymphoma Survivors
Official title: Coping With Lymphoma to Enhance Adjustment and Reduce Stress in Lymphoma Survivors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lymphoma
Posttraumatic Stress Disorder
Posttraumatic Growth
Coping
Resilience
Keywords: lymphoma
survivors
posttraumatic growth
posttraumatic stress
longitudinal
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2011-11-10
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Lymphoma survivors who have completed initial treatment within the last 3 months

Brief summary: Posttraumatic Stress Disorder (PTSD) is a well-documented phenomenon that occurs in cancer survivors. PTSD is known to cause problems with anxiety, depression, and quality of life. Furthermore, there is little treatment available for cancer survivors who suffer from PTSD.

Posttraumatic Growth, however, is a lesser known phenomenon that also occurs in cancer survivors. It is a positive psychological phenomenon that occurs in some people who have suffered a traumatic event--the people who are able to note a "greater appreciation for life", a "stronger relationship with their family/friends," or a "new found level of spirituality" are examples of instances of posttraumatic growth.

Coping with Lymphoma to Enhance Adjustment and Reduce Stress in Survivors (CLEAR Stress) is a study designed to compare the development of PTSD versus the development of Posttraumatic Growth in lymphoma patients at any stage of the cancer experience, regardless of treatment. The hypothesis is that posttraumatic growth, if it is significant, can reduce the impact of PTSD symptoms in the survivor.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Lymphoma (includes Waldenstrom's Macroglobulinemia)
* Can read/write/understand English without a translator

Exclusion Criteria:

* Currently Hospitalized
* Active Psychosis

Primary outcomes:
measure: Posttraumatic Growth
timeFrame: Measured at enrollment
Secondary outcomes:
measure: Posttraumatic Stress Disorder (PTSD)
timeFrame: Measured at Enrollment
Other outcomes:
Locations:
city: New York
country: United States
facility: New York Presbyterian/Weill Cornell Center for Lymphoma and Myeloma
state: New York
Study officials:
affiliation: WCMC Research Fellow
name: Regina A Jacob, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02076854: A Novel Motivational Ecological Momentary Intervention for Anorexia Nervosa
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Eating Disorders
Keywords: eating disorders
anorexia nervosa
treatment
technology
Lead sponsor: Boston University
Sponsor class: OTHER
First posted: 2014-03-04
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to pilot an innovative motivational text-message intervention for individuals with anorexia nervosa and subthreshold anorexia nervosa. Patients will receive personalized motivational text-messages as an adjunct to cognitive behavioral therapy (CBT). CBT will be provided to patients at no cost for the duration of the study. The investigators hypothesize that the text-messages will help increase motivation to change and kilocalorie intake and decrease eating disordered behavior.


Eligibility criteria: Inclusion Criteria:

* Anorexia nervosa/subthreshold anorexia nervosa (i.e., individuals who exhibit significant dietary restraint)
* 18+ years old

Exclusion Criteria:

* BMI \< 16.5
* Medication instability for 6 weeks
* Recent/current suicidal risk
* Comorbid substance abuse or dependence, bipolar disorder, schizophrenia, or mental retardation
* Inability to provide release of information to a medical provider

Primary outcomes:
measure: Change in Motivation to Change Eating Disorder Behaviors
timeFrame: Daily for 8 weeks
measure: Change in Eating Disorder Symptoms
timeFrame: Daily for 8 weeks
measure: Kilocalorie Intake (measured by self-report food records)
timeFrame: Daily for 8 weeks
Secondary outcomes:
measure: Feasibility measured by compliance with daily questionnaire
timeFrame: 8 weeks
measure: Acceptability measured by self-report ratings
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Eating Disorders Program, Boston University
state: Massachusetts
Study officials:
References: